You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 298 Final analysis of the phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
298 Final analysis of the phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020647058
Dec 20203403
Jan 202164011
Feb 2021112017
Mar 2021192023
Apr 2021176029
May 202197057
Jun 20210023
Jul 20210029
Aug 20210021
Sep 20210019
Oct 202194033
Nov 2021138045
Dec 2021106023
Jan 2022145025
Feb 2022206026
Mar 2022234039
Apr 2022202032
May 2022186031
Jun 2022226034
Jul 2022218041
Aug 2022218025
Sep 2022270047
Oct 2022360039
Nov 2022254045
Dec 2022106016
Jan 2023120017
Feb 2023162028
Mar 2023196067
Apr 2023160028
May 2023120018
Jun 2023136021
Jul 202311208
Aug 2023146015
Sep 2023132010
Oct 2023186012
Nov 2023126016
Dec 2023148031
Jan 20245404
Feb 20247802
Mar 2024116015
Apr 2024158016
May 2024108011
Jun 202410108
Jul 202498012
Aug 20247505
Sep 2024116017
Oct 2024164015
Nov 202464019
Dec 2024118011
Jan 2025102023
Feb 202520014
Mar 2025001
Apr 2025006
May 20250011
Jun 2025104
Total740201256